Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03371004 · ClinicalTrials.gov registry record · Phase 1
DM-CHOC-PEN Plus Radiation for Brain Tumors
A Phase 1 study of Advanced Cancer, sponsored by DEKK-TEC.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 3
- Study locations
NCT03371004 is a Phase 1 study of Advanced Cancer that has completed, run by DEKK-TEC. The registered enrollment target is 19 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT03371004, a Phase 1 study of Advanced Cancer, has completed, sponsored by DEKK-TEC.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 3
- Study locations
Study Summary
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial tumor tissue, lacks neurotoxicity and not transported out of the brain via Pgp (p-glycoprotein) (1). DM-CHOC-PEN has completed Phase I/II trials in humans with primary and secondary tumors involving the brain with success. Complete remissions in both primary astrocytoma and metastatic lung and leukemia malignancies. This trial is open for adult subjects with advanced cancer - brain involvement is required.
Conditions Studied
Interventions
- DRUG 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
Study Locations (3)
Louisiana
- Tulane University Medical Center - New Orleans
- Tulane University Medical School - New Orleans
Michigan
- Detroit Clinical Research Centers - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-02-05 |
| Est. Completion | 2022-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03371004
The ClinicalTrials.gov registry entry for NCT03371004 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (92% lower). The listed sponsor is DEKK-TEC, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which 4-Demethyl-4-cholesteryloxycarbonylpenclomedine is the first listed.
NCT03371004 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Louisiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT03371004 about?
NCT03371004 is a clinical study titled "DM-CHOC-PEN Plus Radiation for Brain Tumors". 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial tumor tissue, lacks neurotoxicity and not transported out of the brain ...
What is the current status of trial NCT03371004?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2016-02-05. Estimated completion is 2022-10-01.
What conditions does trial NCT03371004 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT03371004?
The interventions under investigation include: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DRUG).
Who is sponsoring clinical trial NCT03371004?
This trial is sponsored by DEKK-TEC, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03371004 being conducted?
This trial has 3 study locations across Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.